CTOs on the Move

Avante HS

www.avantehs.com

 
Avante is a single source provider of surgical, diagnostic imaging and radiation oncology equipment. Sales, service, repair, parts, installation.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.avantehs.com
  • 1751, Lake Cook Road
    Deerfield, IL USA 60015
  • Phone: 800.979.6142

Executives

Name Title Contact Details

Similar Companies

HepQuant

HepQuant is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atmos-Tech Industries

Atmos- Tech Industries offers high quality controlled environment and cleanroom products and superior customer service.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Arbor Pharmaceuticals

Arbor Pharmaceuticals is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.